Medical
-
Savara Pharmaceuticals has announced positive results from a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. In the 28-day trial, patients… Read more . . .
-
PARI has announced that it has begun supplying nebulizer compressors to patients using its new Kitabis Pak through a program called PARI Provide. Kitabis Pak, which includes generic tobramycin inhalation solution packaged with a PARI… Read more . . .
-
GlaxoSmithKline and Theravance have announced the beginning of the FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI in patients with… Read more . . .
-
Novartis Pharmaceuticals Canada has announced the launch of the Ultibro Breezhaler indacaterol/glycopyrronium bromide DPI for the treatment of COPD in Quebec, the first province in Canada to reimburse the inhaler. The Régie de l’assurance maladie… Read more . . .
-
Mast Therapeutics has announced that the first patients have been dosed in two Phase 2a studies of AIR001 sodium nitrite inhalation solution for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).… Read more . . .
-
Afrezza inhaled insulin is now available by prescription in the US, Sanofi and Mannkind Corporation have announced. The FDA approved the insulin DPI for the treatment of type 1 and type 2 diabetes in June… Read more . . .
-
Evoke Pharma has announced that slower than expected enrollment in a Phase 3 clinical trial of its EVK-001 metoclopramide nasal spray for the treatment of diabetic gastroparesis in women will result in delayed completion of… Read more . . .
-
A study published online in Pediatrics finds that children using a triamcinolone nasal spray for allergic rhinitis grew on average 0.44 cm/year less than children using a placebo nasal spray (5.65 cm/year compared to 6.09… Read more . . .
-
According to Alexza Pharmaceuticals, a Phase 2a study of AZ-002 Staccato alprazolam for the treatment of epilepsy patients with acute repetitive seizures has been initiated. The study will take place in-clinic, though AZ-002 is being… Read more . . .
-
According to Nexus6, a study conducted in New Zealand has shown that 84% of children using the Smartinhaler SmartTrack device, which provides both audio and visual reminders, used their inhalers as prescribed compared to 30%… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden